Bearish
Burning Rock reports 19% decline in Q1 2026 revenue
Burning Rock Biotech experienced an 18.9% decline in Q1 2026 revenue, totaling RMB107.9 million, due to lower volumes in diagnostic testing and pharma...
Bearish
Burning Rock Biotech experienced an 18.9% decline in Q1 2026 revenue, totaling RMB107.9 million, due to lower volumes in diagnostic testing and pharma...